Back to Search
Start Over
Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus
- Source :
- International Journal of Infectious Diseases, Vol 110, Iss, Pp 21-28 (2021)
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Objective To investigate changes in weight following the initiation of antiretroviral therapy in treatment-naive Asian people living with human immunodeficiency virus (PLWH). Methods This retrospective observational study evaluated adult treatment-naive Asian PLWH who started antiretroviral therapy based on an integrase strand transfer inhibitor, a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor at the AIDS Clinical Centre, Tokyo between January 2005 and February 2019. Patients were followed-up until October 2019. Multi-variate linear mixed-effects models were used to generate marginal predictions of weight over time. Predicted weight was reported at 3-month intervals until censoring or for 5 years after treatment initiation. Results Five years after treatment initiation, average weight gain in PLWH who started on dolutegravir-, darunavir- and elvitegravir-based treatment was 5.3 kg, 4.1 kg and 4.6 kg, respectively, while those who started on raltegravir-, lopinavir- and atazanavir-based treatment gained an average of 1.9 kg, 2.1 kg and 2.3 kg, respectively. Average weight gain in PLWH who started treatment with the backbone drugs, tenofovir alafenamide, abacavir and tenofovir disproxil fumarateb was 4.1 kg, 3.0 kg and 3.0 kg, respectively, and those treated with dolutegravir plus tenofovir alafenamide/emtricitabine gained an average of 6.7 kg. Conclusions Antiretroviral-therapy-associated weight gain continued to increase for 5 years following treatment initiation. A combination of dolutegravir and tenofovir alafenamide/emtricitabine was associated with the greatest weight gain.
- Subjects :
- Adult
Microbiology (medical)
medicine.medical_specialty
Anti-HIV Agents
Pyridones
HIV Infections
Infectious and parasitic diseases
RC109-216
Weight Gain
Emtricitabine
Tenofovir alafenamide
chemistry.chemical_compound
Abacavir
Internal medicine
Oxazines
Long term
medicine
Humans
Darunavir
Asian
Reverse-transcriptase inhibitor
business.industry
HIV
Lopinavir
General Medicine
Raltegravir
Antiretroviral therapy
Infectious Diseases
chemistry
Dolutegravir
business
medicine.drug
Subjects
Details
- ISSN :
- 12019712
- Volume :
- 110
- Database :
- OpenAIRE
- Journal :
- International Journal of Infectious Diseases
- Accession number :
- edsair.doi.dedup.....a3dba42de2d85dd03e6812b8b137241c